Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the ...

Pfizer Inc. shares currently offer a dividend yield approaching 7%, ranking among the highest in the S&P 500 index. While the upcoming ex-dividend date of January 23 presents an opportunity for income ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its past three-month return at a 4.1% decline, sharpening focus on its current ...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

A final analysis of a COVID-19 vaccine candidate produced by Pfizer and BioNTech shows that the drug is 95% effective in preventing the coronavirus, and the companies say they hope to apply for ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the ...

An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not ...